A multicenter clinical trial of the effect of raloxifene hydrochloride for the prevention of health care problems caused by bilateral oophorectomy due to endometrial cancer
Not Applicable
- Conditions
- endometrial cancer Osteoporosis
- Registration Number
- JPRN-UMIN000013039
- Lead Sponsor
- Osaka University Graduate School of Medicine, Department of Obstetrics and Gynecology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who refuse participation in this study. Patients who had taken bisphosphonates, estrogen or progestin within the previous 1 year, or vitamin D3, vitamin K2, or ipiriflavone within previous 3 months. Patients who raloxifene, alfacalcidol, or Calcium L-Aspartate Hydrate is contraindicated for. Patients whose lumber BMD was above +2.5 S.D. at the enrollment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method